Fig. 3From: Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)Study protocol depicting the time line and study proceedings between inclusion and hospital dischargeBack to article page